Ines Deleu

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

José Baselga, Mario Campone, Martine Piccart et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +9

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 695 citations · Full text

Medicine, Oncology, Pharmacology +15

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Martine Piccart, Gabriel N. Hortobágyi, Mario Campone et al. · Annals of Oncology · 2014 · 568 citations · Full text

Medicine, Oncology, Pharmacology +12

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

Robert E. Coleman, Dianne M. Finkelstein, Carlos H. Barrios et al. · The Lancet Oncology · 2019 · 257 citations · Full text

Medicine, Oncology, Breast Oncology +9